-
-
-
-
-
-
-
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
-
-
-
-
-
-
-
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
-
-
-
-
-
-
-
Pfizer reafffirms 2026 guidance after CFO transition announcement
-
-
-
-
-
-
-
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
-
-
-
-
-
-
-
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
-
-
-
-
-
-
-
Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
-
-
-
-
-
-
-
Pfizer's ELREXFIO meets primary endpoint in multiple myeloma trial
-
1,219,209 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

